Acknowledgement
This work was supported by the Technology Innovation Program (10063334) funded by the Ministry of Trade, Industry & Energy. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2020R1C1C1009507) and the KIST Institutional Program to S.J.O.
References
- Siegel RL, Miller KD and Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68, 7-30 https://doi.org/10.3322/caac.21442
- Le DT, Hubbard-Lucey VM, Morse MA et al (2017) A blueprint to advance colorectal cancer immunotherapies. Cancer Immunol Res 5, 942-949 https://doi.org/10.1158/2326-6066.CIR-17-0375
- Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372, 2509-2520 https://doi.org/10.1056/NEJMoa1500596
- Cummings JH, Pomare EW, Branch WJ, Naylor CP and Macfarlane GT (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221-1227 https://doi.org/10.1136/gut.28.10.1221
- Topping DL and Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81, 1031-1064 https://doi.org/10.1152/physrev.2001.81.3.1031
- Marques C, Oliveira CS, Alves S et al (2013) Acetateinduced apoptosis in colorectal carcinoma cells involves lysosomal membrane permeabilization and cathepsin D release. Cell Death Dis 4, e507 https://doi.org/10.1038/cddis.2013.29
- Lin Y, Ma CC, Liu CK et al (2016) NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. Oncotarget 7, 29454-29464 https://doi.org/10.18632/oncotarget.8762
- Kucan Brlic P, Lenac Rovis T, Cinamon G, Tsukerman P, Mandelboim O and Jonjic S (2019) Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 16, 40-52 https://doi.org/10.1038/s41423-018-0168-y
- Alex S, Lange K, Amolo T et al (2013) Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon adenocarcinoma cells by activating peroxisome proliferatoractivated receptor gamma. Mol Cell Biol 33, 1303-1316 https://doi.org/10.1128/MCB.00858-12
- Shaib W, Mahajan R and El-Rayes B (2013) Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol 4, 308-318 https://doi.org/10.3978/j.issn.2078-6891.2013.029
- Parada Venegas D, De la Fuente MK, Landskron G et al (2019) Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol 10, 277 https://doi.org/10.3389/fimmu.2019.00277
- Wang G, Huang S, Wang Y et al (2019) Bridging intestinal immunity and gut microbiota by metabolites. Cell Mol Life Sci 76, 3917-3937 https://doi.org/10.1007/s00018-019-03190-6
- Okumura G, Iguchi-Manaka A, Murata R, Yamashita-Kanemaru Y, Shibuya A and Shibuya K (2020) Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells. J Exp Med 217, 1
- Sanchez-Correa B, Valhondo I, Hassouneh F et al (2019) DNAM-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers (Basel) 11, 877 https://doi.org/10.3390/cancers11060877
- Vlahos CJ, Matter WF, Hui KY and Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269, 5241-5248 https://doi.org/10.1016/S0021-9258(17)37680-9
- Kamran N, Takai Y, Miyoshi J, Biswas SK, Wong JS and Gasser S (2013) Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. PLoS One 8, e54406 https://doi.org/10.1371/journal.pone.0054406
- Sung B, Pandey MK, Ahn KS et al (2008) Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaBregulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 111, 4880-4891 https://doi.org/10.1182/blood-2007-10-117994
- Zheng Q, Wang B, Gao J et al (2018) CD155 knockdown promotes apoptosis via AKT/Bcl-2/Bax in colon cancer cells. J Cell Mol Med 22, 131-140 https://doi.org/10.1111/jcmm.13301
- Enloe BM and Jay DG (2011) Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J Neurooncol 102, 225-235 https://doi.org/10.1007/s11060-010-0323-5
- Weiner GJ (2015) Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 15, 361-370 https://doi.org/10.1038/nrc3930
- Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S and Lou Y (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol 11, 39 https://doi.org/10.1186/s13045-018-0582-8
- Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12, 252-264 https://doi.org/10.1038/nrc3239
- Egelston CA, Avalos C, Tu TY et al (2018) Human breast tumor-infiltrating CD8(+) T cells retain polyfunctionality despite PD-1 expression. Nat Commun 9, 4297 https://doi.org/10.1038/s41467-018-06653-9
- Nelson N, Lopez-Pelaez M, Palazon A et al (2019) A cell-engineered system to assess tumor cell sensitivity to CD8(+) T cell-mediated cytotoxicity. Oncoimmunology 8, 1599635
- Wei J, Long L, Zheng W et al (2019) Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471-476 https://doi.org/10.1038/s41586-019-1821-z